Dubin–Johnson syndrome
(Redirected from Conjugated Hyperbilirubinemia)
Dubin–Johnson syndrome is a rare, inherited disorder characterized by chronic jaundice and an increase in conjugated bilirubin in the blood. It is an autosomal recessive condition caused by mutations in the ABCC2 gene, which encodes the multidrug resistance protein 2 (MRP2). This protein is responsible for transporting conjugated bilirubin from the liver cells into the bile.
Pathophysiology[edit | edit source]
The primary defect in Dubin–Johnson syndrome is the impaired secretion of conjugated bilirubin into the bile. This results in the accumulation of conjugated bilirubin in the liver and its subsequent release into the bloodstream, leading to jaundice. The liver in individuals with Dubin–Johnson syndrome typically appears grossly black due to the deposition of a pigment similar to melanin.
Clinical Features[edit | edit source]
Patients with Dubin–Johnson syndrome usually present with mild jaundice that may fluctuate in intensity. The jaundice is often noticed during adolescence or early adulthood. Other symptoms may include fatigue and abdominal discomfort, but many individuals remain asymptomatic. The condition does not typically lead to liver damage or affect life expectancy.
Diagnosis[edit | edit source]
The diagnosis of Dubin–Johnson syndrome is based on clinical presentation, laboratory findings, and genetic testing. Key laboratory findings include elevated levels of conjugated bilirubin in the blood with normal liver enzyme levels. A liver biopsy may show the characteristic dark pigmentation of the liver cells. Genetic testing can confirm mutations in the ABCC2 gene.
Treatment[edit | edit source]
There is no specific treatment for Dubin–Johnson syndrome. Management focuses on monitoring liver function and addressing any symptoms that arise. Patients are advised to avoid factors that may exacerbate jaundice, such as certain medications and alcohol.
Prognosis[edit | edit source]
The prognosis for individuals with Dubin–Johnson syndrome is generally good. The condition is benign and does not lead to significant liver damage or affect overall health. Regular follow-up with a healthcare provider is recommended to monitor liver function.
Related Pages[edit | edit source]
References[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD